DDInter1946 DDInter927
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Voriconazole {u} (Compound) binds {v} (Gene) CYP2B6
Voriconazole {u} (Compound) upregulates {v} (Gene) SELL
Voriconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Voriconazole {u} (Compound) causes {v} (Side Effect) Arthralgia
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Acetohexamide
Voriconazole (Compound) binds CYP2B6 (Gene)
Voriconazole (Compound) upregulates SELL (Gene)
Voriconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Voriconazole (Compound) causes Arthralgia (Side Effect)
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Voriconazole may lead to a major life threatening interaction when taken with Dasatinib
Voriconazole may lead to a major life threatening interaction when taken with Acetohexamide